-
TherapeutAix to take part in Society for Medicines Research (SMR) Meeting
TherapeutAix will be taking part in the Society for Medicines Research (SMR) Meeting on “Innovative Early Clinical Trial Designs and…
-
TherapeutAix to attend the Extracellular Matrix Pharmacology Symposium
TherapeutAix is attending the Extracellular Matrix Pharmacology Symposium hosted by network partner Nordic Bioscience on March 24th – 25th. The online symposium will centre on…
-
Christmas 2020 roundup from the TherapeutAix team
As 2020 draws to a close, the team at TheraeutAix has been looking back and reflecting on the last 12…
-
Drug Development in IPF
Drug development in Idiopathic Pulmonary Fibrosis (IPF) remains challenging. The pharmacological properties of the two approved drugs, pirfenidone and nintedanib,…
-
Alderley Analytical and Peak Proteins join the TherapeutAix Network
Following a recent collaboration, TherapeutAix is delighted to announce the addition of Alderley Analytical and Peak Proteins as network partners.…
-
TherapeutAix turns two!
This September, TherapeutAix is two years old. Here, we look back on the past 12 months, and take a sneak…
-
COVID-19 and Learning about Lung Fibrosis
Emerging understanding of the clinical course of COVID-19 may enable a better understanding of fibrosis in the lung. Future learnings…
-
Common denominators in fibrotic lung disease
With fibrotic disease being one of our areas of interest, it has been highly interesting to follow the news in…
-
TherapeutAix to attend Fraunhofer ‘Models of Lung Disease’ seminar
Two directors of TherapeutAix, Simon Cruwys and Darcey Black, will be attending the 19th Fraunhofer Seminar titled ‘Models of Lung…
-
2019 Round Up – A Full Year!
With 2019 coming to a close, we’re reflecting on a year filled with activities including: advising clients on their projects,…
